268 related articles for article (PubMed ID: 26303609)
21. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
Khan A; Sirrs SM; Bichet DG; Morel CF; Tocoian A; Lan L; West ML;
Drugs R D; 2021 Dec; 21(4):385-397. PubMed ID: 34542871
[TBL] [Abstract][Full Text] [Related]
22. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
23. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.
Germain DP; Elliott PM; Falissard B; Fomin VV; Hilz MJ; Jovanovic A; Kantola I; Linhart A; Mignani R; Namdar M; Nowak A; Oliveira JP; Pieroni M; Viana-Baptista M; Wanner C; Spada M
Mol Genet Metab Rep; 2019 Jun; 19():100454. PubMed ID: 30775256
[TBL] [Abstract][Full Text] [Related]
24. Globotriaosylsphingosine (lyso-Gb
Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
[TBL] [Abstract][Full Text] [Related]
25. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
26. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
[TBL] [Abstract][Full Text] [Related]
27. A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease.
Hwang S; Lee BH; Kim WS; Kim DS; Cheon CK; Lee CH; Choi Y; Choi JH; Kim JH; Yoo HW
Medicine (Baltimore); 2022 Sep; 101(37):e30345. PubMed ID: 36123934
[TBL] [Abstract][Full Text] [Related]
28. Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.
Pisani A; Spinelli L; Visciano B; Capuano I; Sabbatini M; Riccio E; Messalli G; Imbriaco M
JIMD Rep; 2013; 9():41-48. PubMed ID: 23430546
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
30. Treatment switch in Fabry disease- a matter of dose?
Lenders M; Nordbeck P; Canaan-Kühl S; Kreul L; Duning T; Lorenz L; Pogoda C; Brand SM; Wanner C; Brand E
J Med Genet; 2021 May; 58(5):342-350. PubMed ID: 32522756
[TBL] [Abstract][Full Text] [Related]
31. Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype.
Hopkin RJ; Feldt-Rasmussen U; Germain DP; Jovanovic A; Martins AM; Nicholls K; Ortiz A; Politei J; Ponce E; Varas C; Weidemann F; Yang M; Wilcox WR
Mol Genet Metab Rep; 2020 Dec; 25():100670. PubMed ID: 33163363
[TBL] [Abstract][Full Text] [Related]
32. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.
Krämer J; Lenders M; Canaan-Kühl S; Nordbeck P; Üçeyler N; Blaschke D; Duning T; Reiermann S; Stypmann J; Brand SM; Gottschling T; Störk S; Wanner C; Sommer C; Brand E; Weidemann F
Nephrol Dial Transplant; 2018 Aug; 33(8):1362-1372. PubMed ID: 29186537
[TBL] [Abstract][Full Text] [Related]
33. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
Morimoto H; Ito Y; Yoden E; Horie M; Tanaka N; Komurasaki Y; Yamamoto R; Mihara K; Minami K; Hirato T
Mol Genet Metab; 2018 Sep; 125(1-2):153-160. PubMed ID: 30054149
[TBL] [Abstract][Full Text] [Related]
34. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
Vedder AC; Linthorst GE; Houge G; Groener JE; Ormel EE; Bouma BJ; Aerts JM; Hirth A; Hollak CE
PLoS One; 2007 Jul; 2(7):e598. PubMed ID: 17622343
[TBL] [Abstract][Full Text] [Related]
36. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.
Schiffmann R; Askari H; Timmons M; Robinson C; Benko W; Brady RO; Ries M
J Am Soc Nephrol; 2007 May; 18(5):1576-83. PubMed ID: 17409308
[TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
38. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
39. Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.
Kanai T; Ito T; Odaka J; Saito T; Aoyagi J; Betsui H; Yamagata T
Eur J Pediatr; 2016 Mar; 175(3):427-31. PubMed ID: 26454753
[TBL] [Abstract][Full Text] [Related]
40. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib RP; Nascimento P; Pastores GM
Cochrane Database Syst Rev; 2013 Feb; (2):CD006663. PubMed ID: 23450571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]